PROGNOSTIC VALUE OF THE DENSITY OF TUMOR-INFILTRATING LYMPHOCYTES AND ITS ASSOCIATION WITH CLINICAL-MORPHOLOGICAL FEATURES OF COLON ADENOCARCINOMAS
DOI:
https://doi.org/10.15407/exp-oncology.2024.01.045Keywords:
tumor-infiltrating lymphocytes, colon cancer, overall survival, prognosis, adenocarcinomaAbstract
Aim. To study the prognostic value of the density of tumor-infiltrating lymphocytes (TILs) and its association with other clinical-morphological parameters in colon adenocarcinomas (CAC). Materials and Methods. 236 CAC samples were examined. TILs density was estimated as the percentage of tumor stromal area occupied by TILs. By the index of TILs density, the patients were divided into 3 groups: TILs 0—9% (n = 88); TILs 10—39% (n = 106); TILs > 40% (n = 42). Dependent on this index, their overall survival (OS) was analyzed. Results. Kaplan — Meier curves revealed a significant (p < 0.001) difference in the OS for patients with different TILs infiltration intensities. Multivariate Cox’s proportional hazard regression model analysis has confirmed that patients with moderate TILs density (HR 0.57, 95% CI 0.34—0.96, p = 0.035) had better OS rates compared to low TILs density. TILs were associated with the stage (p < 0.001), lymph node metastasis pN (p < 0.001), distant metastasis M (p < 0.001), and the patient’s outcome (p < 0.001). Conclusion. TILs can be considered an additional prognostic tool during regular histological examination and are strongly associated with the most significant clinical-morphological features of CAC.
References
Cancer Today. Iarc.fr. Accessed March 11, 2024. https://gco.iarc.fr/today/data/factsheets/cancers/8-Colon-fact-sheet.pdf.
Henderson RH, French D, Maughan T, et al. The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study. Lancet Gastroenterol Hepatol. 2021;6(9):709-722. https://doi.org/10.1016/s2468-1253(21)00147-3
Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683-691. https://doi.org/10.1136/gutjnl-2015-310912
Guren MG. The global challenge of colorectal cancer. Lancet Gastroenterol Hepatol. 2019;4(12):894-895. https://doi.org/10.1016/S2468-1253(19)30329-2
Schreuders EH, Ruco A, Rabeneck L. Colorectal cancer screening: a global overview of existing programs. Gut. 2015;64(10):1637-1649. https://doi.org/10.1136/gutjnl-2014-309086
Kaminski MF, Robertson DJ, Senore C, Rex DK. Optimizing the quality of colorectal cancer screening worldwide. Gastroenterology. 2020;158(2):404-417. https://doi.org/10.1053/j.gastro.2019.11.026
Mei WJ, Mi M, Qian J, et al. Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: A narrative review. Front Immunol. 2022;13:1019582. https://doi.org/10.3389/fimmu.2022.1019582
Lenz HJ, Van Cutsem E, Luisa Limon M, et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: The phase II CheckMate 142 study. J Clin Oncol. 2022;40(2):161-170. https://doi.org/10.1200/JCO.21.01015
Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2021;18(4):842-859. https://doi.org/10.1038/s41423-020-00565-9
Bai Z, Zhou Y, Ye Z, et al. Tumor-infiltrating lymphocytes in colorectal cancer: The fundamental Indication and application on immunotherapy. Front Immunol. 2021;12:808964. https://doi.org/10.3389/fimmu.2021.808964
International Agency for Research on Cancer, World Health Organization, International Academy of Pathology. WHO Classification of Tumours. Digestive System Tumours: WHO Classification of Tumours, Volume 1. 1st ed. (Elder DE, ed.). IARC; 2019: 157-177.
van Pelt GW, Kjær-Frifeldt S, van Krieken JHJM, et al. Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations. Virchows Arch. 2018;473(4):405-412. https://doi.org/10.1007/s00428-018-2408-z
Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259-271. https://doi.org/10.1093/annonc/mdu450
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452-458. https://doi.org/10.1038/bmt.2012.244
Argilés G, Tabernero J, Labianca R. Localized colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291-1305. https://doi.org/10.1016/j.annonc.2020.06.022
O’Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29(25):3381-3388. https://doi.org/10.1200/JCO.2010.34.3426
Benson AB 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408-3419. https://doi.org/10.1200/JCO.2004.05.063
Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22(10):1797-1806. https://doi.org/10.1200/JCO.2004.09.059
Bader JE, Voss K, Rathmell JC. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. Mol Cell. 2020;78(6):1019-1033. https://doi.org/10.1016/j.molcel.2020.05.034
Valkenburg KC, De Groot AE, Pienta KJ. Targeting the tumor stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018;15(6):366-381. https://doi.org/10.1038/s41571-018-0007-1
Chen Y, Zheng X, Wu C. The role of the tumor microenvironment and treatment strategies in colorectal cancer. Front Immunol. 2021;12:792691. https://doi.org/10.3389/fimmu.2021.792691
Mesker WE, Junggeburt JMC, Szuhai K, et al. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol. 2007;29(5):387-398. https://doi.org/10.1155/2007/175276
Zakhartseva LM, Yanovytska MA. Prognostic value of tumor stroma ratio in triple negative breast cancer. Wiad Lek. 2021;74(3 cz 2):565-571.
Li H, Yuan SL, Han ZZ, et al. Prognostic significance of the tumor-stroma ratio in gallbladder cancer. Neoplasma. 2017;64(04):588-593. https://doi.org/10.4149/neo_2017_413
Leppänen J, Lindholm V, Isohookana J, et al. Tenascin C, fibronectin, and tumor-stroma ratio in pancreatic ductal adenocarcinoma. Pancreas. 2019;48(1):43-48. https://doi.org/10.1097/MPA.0000000000001195
Xiong Y, Wang Y, Tiruthani K. Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer. Nanomedicine. 2019;21(102034):102034. https://doi.org/10.1016/j.nano.2019.102034
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899. https://doi.org/10.1016/j.cell.2010.01.025
Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58(16):3491-3494.
Kawai O, Ishii G, Kubota K, et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 2008;113(6):1387-1395. https://doi.org/10.1002/cncr.23712
Kondratiev S, Sabo E, Yakirevich E, Lavie O, Resnick MB. Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res. 2004;10(13):4450-4456. https://doi.org/10.1158/1078-0432.CCR-0732-3
Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40-50. https://doi.org/10.1016/S1470-2045(17)30904-X
Zakhartseva LM, Yanovytska MO. Tumor-infiltrating lymphocytes in triple negative breast cancer. Pathologia. 2020;0(3). https://doi.org/10.14739/2310-1237.2020.3.221722
Dülgar Ö, İlvan Ş, Turna ZH. Prognostic factors and tumor infiltrating lymphocytes in triple negative breast cancer. Eur J Breast Health. 2020;16(4):276-281. https://doi.org/10.5152/ejbh.2020.5305
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
